tedizolid. 19 20 21 22 Mycobacterium abscessus has emerged as a significant pathogen responsible for chronic 23 pulmonary infections in cystic fibrosis (CF) patients, which are difficult to treat due to 24 resistance to a broad range of antibiotics. The initial phase of the recommended treatment 25 in CF patients includes imipenem used without any β-lactamase inhibitor in spite of the 26 production of the β-lactamase Bla Mab . Here, we determine whether the addition of 27 tedizolid, a once-daily oxazolidinone, improves the activity of imipenem alone or in 28 combination with a β-lactamase inhibitor, avibactam, and rifabutin. 29 The activity of the drugs was evaluated against M. abscessus CIP104536 by determining in 30 vitro and intracellular antibacterial activities. The impact of Bla Mab inhibition by avibactam 31 on antibiotic activity was assessed by comparing CIP104536 and its β-lactamase-deficient 32 derivative (∆bla Mab ). 33 The minimal inhibitory concentrations (MICs) of tedizolid against M. abscessus CIP104536 34 and ∆bla Mab were 4 µg/mL. Tedizolid combined with imipenem showed a moderate 35 synergistic effect with fractional inhibitory concentration (FIC) indexes of 0.41 and 0.38 for 36 CIP104536 and ∆bla Mab , respectively. For both strains, the addition of tedizolid at 2 µg/mL, 37 corresponding to the peak serum concentration, increased the intracellular efficacy of 38 imipenem at 8 and 32 µg/mL. Addition of avibactam and rifabutin improved the activity of 39 the imipenem-tedizolid combination against CIP104536S. 40 The imipenem-tedizolid combination should be further considered for the treatment of M. 41 abscessus pulmonary infections in CF patients. The efficacy of the treatment might benefit 42 from the use of a β-lactamase inhibitor, such as avibactam, and the addition of rifabutin. 43 44 45 46
3 Nontuberculous mycobacteria (NTM) have been increasingly isolated from the lungs of 47 cystic fibrosis (CF) patients (1-4) with a prevalence estimated at 11 to 13% (1, 5) . Among 48 NTM, M. abscessus, a rapidly growing mycobacterium, is the predominant species isolated in 49 these patients (40 to 50%) (2,6). Chronic pulmonary M. abscessus infections have been 50 associated with increased lung function decline in CF patients (5) . 51
The treatment is particularly complex and difficult since M. abscessus is intrinsically 52 resistant to a broad range of antibiotics, including those used for the treatment of 53 tuberculosis (7, 8) . In 2016, the US Cystic Fibrosis Foundation and European Cystic Fibrosis 54
Society have established recommendations for the management of NTM in CF patients (9) . 55
The typical treatment schedule consists of an initial phase with the combination of a 56 carbapenem (imipenem), a macrolide (azithromycin), an aminoglycoside (amikacin), and a 57 glycylcycline (tigecycline) for a duration of 3 months (9). Four per os drugs (azithromycin, 58 minocycline, clofazimine, and moxifloxacin) are proposed for the continuation phase for at 59 least 12 months (9). In spite of these lengthy courses of antibiotics, the prognosis of 60 pulmonary infections is poor in the context of CF with a cure rate of 30 to 50% (10,11). In 61 case of macrolide resistance, present in 40 to 60% of the isolates (12), the rate of 62 bacteriological eradication is in the order of 25% (10). In this context, there is an urgent need 63 to identify additional therapeutic options. This could be achieved in the short term by 64 repurposing existing drugs approved for the treatment of other bacterial infections. 65 M. abscessus isolates produce a broad-spectrum β-lactamase Bla Mab , which hydrolyzes 66 most β-lactams, except cefoxitin, and inactivates imipenem at a very slow rate (13, 14) . 67
Imipenem is currently used in the absence of any β-lactamase inhibitor although Bla Mab was 68 recently shown to limit the intracellular activity of imipenem in human macrophages 69 (13, 15, 16) . First generation of β-lactamase inhibitors, clavulanate, tazobactam, and 70 4 sulbactam, are inactive against Bla Mab (17). However, Bla Mab is inhibited by a novel β-71 lactamase inhibitor, avibactam (13), which has been developed in combination with 72 ceftazidime for the treatment of infections due to multi-drug resistant Enterobacteriaceae 73 (18). Avibactam extends the spectrum of β-lactams active against M. abscessus (13, 15) and 74 improves the efficacy of imipenem, both in macrophages and in zebrafish embryos (16) . 75
Linezolid, a first-generation oxazolidinone antibiotic, is an important therapeutic 76 option for infections caused by resistant Gram-positive bacteria (19). In Mycobacterium 77 tuberculosis, clinical efficacy of linezolid has been reported in most difficult-to-treat MDR 78 and XDR-cases (20,21). Linezolid has been positioned by WHO in the group 5 of anti-TB drugs 79 for the treatment of MDR and XDR-TB cases (22). In case of intolerance to drugs of the 80 reference treatment for M. abscessus in CF patients, linezolid is also proposed during the 81 continuation phase (9), in spite of high minimal inhibitory concentrations (MICs) comprised 82 between 16 and 64 µg/mL (7,23,24). However, the high frequency and severity of adverse 83 events limit the long-term use of linezolid (20). Tedizolid is a recently developed once-daily 84 oxazolidinone antibiotic, which has been approved for the treatment of acute bacterial skin 85 and soft tissue infections (25). In M. abscessus, a recent in vitro study has shown that 86 tedizolid has a better in vitro activity compared to linezolid, as the MIC 50 s and MIC 90 s of 87 tedizolid (2 and 8 µg/mL, respectively) were 2-to 16-fold lower than those of linezolid (24). 88
In this study, we have investigated the interest of repurposing tedizolid for M. 89 abscessus infections in combination with imipenem alone or with imipenem, avibactam and 90 rifabutin. We report the in vitro and intracellular antibacterial activities of various 91 combinations of these four drugs. The impact of β-lactamase production was assessed by 92 comparing M. abscessus CIP104536 and a derivative obtained by deletion of the gene 93 encoding Bla Mab . 94
5

RESULTS
95
MICs of tedizolid and imipenem and synergy between these drugs. The MIC of tedizolid 96 was 4 µg/mL against both M. abscessus CIP104536 and its β-lactamase deficient (Δbla Mab ) 97 derivative ( Table 1 ). The MICs of imipenem were 4 µg/mL and 2 µg/mL against CIP104536 98 and its Δbla Mab derivative. Against CIP104536 (Table 1) µg/mL) corresponding to the peak serum concentration for an administration of 200 mg per 106 day (27) and imipenem at 2 fold the MIC (8 µg/mL). Against CIP104536, tedizolid alone had 107 no effect in the reduction of CFUs ( Fig. 1A and Table S1 ). A 0.7 Log 10 -reduction of CFUs was 108 observed for imipenem alone at 8 µg/mL. The addition of tedizolid did not increase the 109 bacterial killing for imipenem (1.0 Log 10 -reduction of CFUs). Similar results were obtained for 110 Δbla Mab derivative of CIP104536 ( Fig. 1B and Table S2 ). Since the addition of tedizolid to 111 imipenem did not improve the activity of imipenem against M. abscessus CIP104536, we 112 investigated the benefit of adding avibactam (4 µg/mL) ( Fig. 1C and Table S3 ). Avibactam did 113 not potentiate the killing by imipenem alone. The triple combination of imipenem-tedizolid-114 avibactam was not more active than the imipenem-tedizolid combination. 115
To conclude on the in vitro activity of the drugs, tedizolid did not increase the activity 116 of imipenem against M. abscessus. The activity of imipenem or imipenem-tedizolid is not 117 6 improved by the addition of avibactam. None of the combination was bactericidal against 118 both strains. 119 120 Intramacrophage activity of tedizolid alone, in combination with imipenem, or in 121 combination with imipenem and avibactam. In the absence of antibiotic, M. abscessus 122 CIP104536 grew in the macrophages, leading to a 143-fold increase in the number of CFUs in 123 48 h ( Fig. 2A , Table S4 ). Tedizolid at 2 µg/mL partially prevented intramacrophage growth 124 (6.85-versus 143-fold increase in the number of CFUs; P < 0.05). Imipenem at 8 µg/mL was 125 more active than tedizolid (1.75-versus 6.85-fold increase in CFUs; P < 0.05). Increasing the 126 concentration of imipenem from 8 µg/mL to 32 µg/mL increased the activity of this drug but 127 the difference was not statically significant (1.75-versus 0.74-fold change in CFUs; P = 0.13). 128
The combination of tedizolid and imipenem (8 µg/mL) was more active than imipenem alone 129 (0.10-versus 1.75-fold change in CFUs; P < 0.05). Of note, the combination of imipenem (8 130 µg/mL) and tedizolid (2 µg/mL) achieved 90% killing of M. abscessus in the macrophage. 131
Increasing the concentration of imipenem from 8 µg/mL to 32 µg/mL did not improve killing 132 (90% versus 79%; P = 0.13). 133
The combinations of imipenem and tedizolid were also tested against the isogenic 134 strain M. abscessus CIP104536 Δbla Mab to evaluate the impact of the production of the β-135 lactamase Bla Mab on the intracellular activity of the drugs ( Fig. 2A and Table S5 ). Tedizolid 136 alone displayed similar activity against Δbla Mab and CIP104536 (14.27-versus 6.85-fold 137 change, P = 0.72, Table S6 ). Deletion of bla Mab significantly improved the activity of 138 imipenem alone at the two concentrations tested (0.17-fold versus 1.75-fold change at 8 139 µg/mL and 0.14-fold versus 0.74-fold change at 32 µg/mL; P < 0.05 for both comparisons). 140 7 The addition of tedizolid improved the activity of imipenem at 8 and 32 µg/mL against the 141 Δbla Mab derivative leading to 95% and 96% of killing respectively. At a low dose of imipenem, 142 production of Bla Mab moderately reduced the activity of imipenem-tedizolid but the 143 difference was not statistically significant (95% versus 90% killing, respectively; P = 0.37). 144
This difference was slightly more pronounced for the combination involving the high dose 145
imipenem (96% and 79% killing) reaching statistical significance (P < 0.05). 146
Since production of Bla Mab reduced the efficacy of the imipenem-tedizolid combination, 147
we tested whether inhibition of Bla Mab by avibactam at 16 µg/mL could improve the 148 intramacrophage activity of the combination against M. abscessus CIP104536 ( Fig. 2B ; Table  149 S7). As previously described (16,26), the activity of imipenem at 8 µg/mL was improved by 150 avibactam leading to a 0.32-fold change in the number of CFUs. This fold change is similar to 151 that observed for the imipenem-tedizolid combination (0.28-fold change). The triple 152 combination comprising tedizolid, imipenem, and avibactam was the more active regimens 153 leading to a 97% of killing. Increasing the concentration of imipenem from 8 µg/ml to 32 154 µg/mL did not improve the activity of the triple combination. In conclusion, the addition of 155 avibactam significantly increased the activity of the imipenem-tedizolid combination if 156 imipenem is used at a low concentration (8 µg/ml). 157 158 Impact of the addition of rifabutin on the intramacrophage activity of tedizolid alone or in 159 combination with imipenem or with imipenem-avibactam. We have recently reported that 160 rifabutin increased the activity of imipenem against M. abscessus in the macrophage model 161 (26). We have evaluated the benefit of adding rifabutin to the combination imipenem-162 tedizolid with or without avibactam ( Fig. 3, and Table S8 ). Rifabutin at 1 µg/mL, 163 corresponding to concentration achievable in the serum, significantly improved the activity 164 8 of the triple combination imipenem-avibactam-tedizolid (0.09-fold versus 0.28-fold change; 165 P < 0.05). Increasing concentration of rifabutin (8 µg/mL,) did not improve the activity of the 166 quadruple combination ( Fig S1) . 167 168 Impact of sub-concentration of tedizolid on β-lactamase activity. To explore the 169 mechanism underlying the improved activity of imipenem when combined to tedizolid, we 170 determined the β-lactamase specific activity in crude bacterial extracts using nitrocefin as 171 the substrate (Fig. 4) . Growth of M. abscessus CIP104536 in presence of sub-concentrations 172 of tedizolid (1 µg/ml and 2 µg/ml, corresponding to ¼ and ½ of the MIC) decreased the β-173 lactamase specific activity (from 50 to 28 and 14 nmol/min/mg, respectively; P < 0.05 for 174 both comparison). These results suggest that a decrease in the production of the β- intramacrophage accumulation may account for the observed activity of tedizolid in the 190 macrophage model at a concentration lower than the MIC (4 µg/mL). In vitro, the 191 combination of imipenem and tedizolid was moderately synergistic (Table 1) observed in vitro (Fig. 4) . In the macrophage, the extent of killing of M. abscessus CIP104536 203 by the imipenem-tedizolid combination was further increased by the addition of avibactam. 204
Thus, both tedizolid and avibactam should be considered as potential therapeutic options to 205 improve the activity of imipenem. 206
Since it has recently been shown that rifabutin has a promising activity against M. 207 abscessus (26,29), the second objective of our study was to compare the activity of tedizolid 208 and rifabutin and to evaluate whether combinations comprising these two drugs have a 209 potential therapeutic interest. In the macrophage, tedizolid and rifabutin were similarly 210 active in improving the activity of imipenem alone (Fig. 5) . Testing tedizolid and rifabutin 211 ( Fig. 3) revealed the benefit of combining these two drugs with imipenem. 212
In conclusion, the assessment of the efficacy of drug combinations in the macrophage 213 indicates that imipenem-avibactam-tedizolid-rifabutin should be clinically evaluated, 214 particularly in infections due to macrolide-resistant M. abscessus. The advantage of tedizolid 215 and rifabutin as potential therapeutic options for the treatment of lung infections in CF 216 patients is also supported by the relatively low toxicity of these drugs and their oral route of 217 administration. Thus, tedizolid and rifabutin could in particular be considered as alternatives 218 to amikacin in the recommended treatment. 
